ES2629509T3 - Integración específica de sitio - Google Patents
Integración específica de sitio Download PDFInfo
- Publication number
- ES2629509T3 ES2629509T3 ES13729962.4T ES13729962T ES2629509T3 ES 2629509 T3 ES2629509 T3 ES 2629509T3 ES 13729962 T ES13729962 T ES 13729962T ES 2629509 T3 ES2629509 T3 ES 2629509T3
- Authority
- ES
- Spain
- Prior art keywords
- gene
- host cell
- cell
- interest
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663147P | 2012-06-22 | 2012-06-22 | |
| US201261663147P | 2012-06-22 | ||
| EP12185330.3A EP2711428A1 (en) | 2012-09-21 | 2012-09-21 | Site-specific integration |
| EP12185330 | 2012-09-21 | ||
| PCT/EP2013/062859 WO2013190032A1 (en) | 2012-06-22 | 2013-06-20 | Site-specific integration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2629509T3 true ES2629509T3 (es) | 2017-08-10 |
Family
ID=46888327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13729962.4T Active ES2629509T3 (es) | 2012-06-22 | 2013-06-20 | Integración específica de sitio |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10280436B2 (enExample) |
| EP (2) | EP2711428A1 (enExample) |
| JP (1) | JP6053923B2 (enExample) |
| KR (1) | KR101761709B1 (enExample) |
| CN (1) | CN104379753B (enExample) |
| AU (1) | AU2013279333C1 (enExample) |
| BR (1) | BR112014032299B1 (enExample) |
| CA (1) | CA2876280C (enExample) |
| DK (1) | DK2864489T3 (enExample) |
| EA (1) | EA034039B1 (enExample) |
| ES (1) | ES2629509T3 (enExample) |
| IL (1) | IL236347A0 (enExample) |
| IN (1) | IN2014MN02518A (enExample) |
| MX (1) | MX351727B (enExample) |
| PL (1) | PL2864489T3 (enExample) |
| SG (1) | SG11201408576QA (enExample) |
| TW (1) | TWI523946B (enExample) |
| WO (1) | WO2013190032A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| US10774353B2 (en) * | 2015-04-27 | 2020-09-15 | Momenta Pharmaceuticals, Inc. | Methods of manufacturing therapeutic proteins |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| US11530277B2 (en) | 2016-04-20 | 2022-12-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| CN119242587A (zh) * | 2017-02-17 | 2025-01-03 | 隆萨有限公司 | 难以表达的蛋白质的多位点特异性整合细胞 |
| WO2018150271A1 (en) | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Mammalian cells for producing adeno-associated viruses |
| GB201703418D0 (en) * | 2017-03-03 | 2017-04-19 | Ge Healthcare Bio Sciences Ab | Method for cell line development |
| WO2018167621A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| CN107557390A (zh) * | 2017-09-18 | 2018-01-09 | 江南大学 | 一种筛选cho细胞系高表达位点的方法 |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| JP7549582B2 (ja) * | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| EP3980544A1 (en) * | 2018-12-21 | 2022-04-13 | F. Hoffmann-La Roche AG | Targeted integration of nucleic acids |
| SG11202110076PA (en) * | 2019-04-02 | 2021-10-28 | Chugai Pharmaceutical Co Ltd | Method of introducing target-specific foreign gene |
| WO2021094461A1 (en) | 2019-11-14 | 2021-05-20 | Lonza Ltd | Methods of cell selection |
| KR102335242B1 (ko) * | 2020-05-22 | 2021-12-02 | 인천대학교 산학협력단 | Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포 |
| WO2022023972A1 (en) | 2020-07-30 | 2022-02-03 | Pfizer Inc. | Cells having gene duplications and uses thereof |
| US20240327496A1 (en) | 2021-08-02 | 2024-10-03 | Pfizer Inc. | Improved Expression Vectors and Uses Thereof |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| EP4473096A1 (en) | 2022-02-02 | 2024-12-11 | Pfizer Inc. | Cysteine prototrophy |
| CN118726475B (zh) * | 2023-03-28 | 2025-07-08 | 深圳太力生物技术有限责任公司 | 核酸、重组载体、靶向整合细胞、基因表达方法和应用 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| WO2025115876A1 (ja) | 2023-11-29 | 2025-06-05 | 富士フイルム株式会社 | 細胞の作出方法、細胞及びタンパク質の製造方法 |
| KR20260103112A (ko) | 2023-11-29 | 2026-07-02 | 후지필름 가부시키가이샤 | 탐색 방법, 세포의 작출 방법, 세포의 선별 방법, 세포 및 세포 생산물의 제조 방법 |
| WO2026162509A1 (en) | 2025-01-28 | 2026-08-06 | Selexis Sa | Integration regions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| WO1998048005A1 (en) | 1997-04-24 | 1998-10-29 | University Of Washington | Targeted gene modification by parvoviral vectors |
| JP4926054B2 (ja) * | 2004-07-20 | 2012-05-09 | シムフォゲン・アクティーゼルスカブ | 抗−ＲｈＤ組換えポリクローナル抗体及び製造方法 |
| JP4665115B2 (ja) * | 2004-08-06 | 2011-04-06 | 独立行政法人理化学研究所 | 骨・関節疾患感受性遺伝子およびその用途 |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
-
2012
- 2012-09-21 EP EP12185330.3A patent/EP2711428A1/en not_active Withdrawn
-
2013
- 2013-06-20 EP EP13729962.4A patent/EP2864489B1/en active Active
- 2013-06-20 BR BR112014032299-6A patent/BR112014032299B1/pt not_active IP Right Cessation
- 2013-06-20 WO PCT/EP2013/062859 patent/WO2013190032A1/en not_active Ceased
- 2013-06-20 PL PL13729962T patent/PL2864489T3/pl unknown
- 2013-06-20 DK DK13729962.4T patent/DK2864489T3/en active
- 2013-06-20 EA EA201590068A patent/EA034039B1/ru not_active IP Right Cessation
- 2013-06-20 SG SG11201408576QA patent/SG11201408576QA/en unknown
- 2013-06-20 ES ES13729962.4T patent/ES2629509T3/es active Active
- 2013-06-20 CA CA2876280A patent/CA2876280C/en active Active
- 2013-06-20 CN CN201380032837.8A patent/CN104379753B/zh active Active
- 2013-06-20 US US14/409,283 patent/US10280436B2/en active Active
- 2013-06-20 MX MX2014015612A patent/MX351727B/es active IP Right Grant
- 2013-06-20 KR KR1020157000511A patent/KR101761709B1/ko active Active
- 2013-06-20 JP JP2015517758A patent/JP6053923B2/ja active Active
- 2013-06-20 AU AU2013279333A patent/AU2013279333C1/en not_active Ceased
- 2013-06-20 IN IN2518MUN2014 patent/IN2014MN02518A/en unknown
- 2013-06-21 TW TW102122188A patent/TWI523946B/zh not_active IP Right Cessation
-
2014
- 2014-12-18 IL IL236347A patent/IL236347A0/en active IP Right Grant
-
2018
- 2018-10-31 US US16/176,525 patent/US11326185B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11326185B2 (en) | Site-specific integration | |
| AU2017268458B2 (en) | Methods for breaking immunological tolerance using multiple guide RNAS | |
| CN115989041A (zh) | 经工程化为表达adar1的细胞和非人动物及其用途 | |
| EP2898077B1 (en) | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences | |
| MXPA03010626A (es) | Plataformas a base de cromosomas. | |
| CN103834686B (zh) | 高效克隆筛选表达载体、其制备方法及用途 | |
| US20220089775A1 (en) | Multiply auxotrophic cell line for the production of recombinant proteins and methods thereof | |
| WO2019096054A1 (zh) | 一种筛选谷氨酰胺合成酶缺陷型hek293细胞株的方法 | |
| JP4998814B2 (ja) | Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法 | |
| JP2010522549A (ja) | 目的のポリヌクレオチドの発現を増強するためのポリヌクレオチド | |
| JP4568378B2 (ja) | 遺伝子発現安定化エレメント | |
| CN120035660A (zh) | 基因转移效率增强的转座酶突变体 | |
| CN105695509B (zh) | 一种获得高纯度心肌细胞的方法 | |
| CN111040028B (zh) | 能促进较大基因表达的Bcl2突变体及应用 | |
| HK1202580B (en) | Site-specific integration | |
| US20230313173A1 (en) | Systems and methods for identifying cells that have undergone genome editing | |
| RU2829155C2 (ru) | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк | |
| JP3376412B2 (ja) | 活性型リボザイムの選択方法 | |
| WO2006080248A1 (ja) | 線状哺乳類人工染色体及びその構築方法 | |
| KR20150145865A (ko) | Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법 |